Dariohealth reports record quarterly revenues in its 2022 first quarter

Total q1 revenue of $8.06 million increased 124% over the comparable prior year period and 34% sequentially over q4 2021 accelerated business-to-business (b2b) transformation with 14 new b2b accounts in q1 2022, including two health plans expanded gaap gross margin to 49.4% and non-gaap gross margin to 61% improved overall financial profile with increasing b2b revenue and reduced operating costs as b2b business matures resulting in a lower net loss compared to q4 2021 company to host conference call and webcast 8:30 am et today new york , may 12, 2022 /prnewswire/ -- dariohealth corp. (nasdaq: drio), a leader in the global digital therapeutics (dtx) market, today reported financial results for the first quarter 2022 and provided a corporate and commercial update. "our first quarter results reflect our increasingly successful transition to a b2b model with growing revenue and gross margins," stated erez raphael, chief executive officer of dario.
DRIO Ratings Summary
DRIO Quant Ranking